Re: Resverlogix presenting at Vascular Discovery 2019 next week
in response to
by
posted on
May 10, 2019 05:09PM
The CRP study looks particularly interesting to me.
I/we used to look at CRP as just a marker of inflammation.
Research is changing that view....
“The literature suggests that CRP binds to damaged cell membranes and contributes to the inflammatory response (59), with CRP molecules becoming associated with terminal complement complexes, especially in atherosclerotic lesions (60). Lagrand et al. (61) provided evidence that CRP localizes to infarcted heart tissue and promotes local complement activation, triggering further damage to the heart tissue.”